Latest Share Chat

REMOVE ADS

Hutchmed Share News (HCM)

Hutchmed Information

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes

Get Live Data

168.00 3.25 (1.97%)

Bid:

158.00

Ask:

162.00

Spread: 4.00 (2.532%)

Market Cap: £1.44b

Last checked at -

Intraday Hutchmed Share Chart

REMOVE ADS

Hutchmed News

LONDON BRIEFING: Chrysalis settles claims with Revolution Beauty

(Alliance News) - London's FTSE 100 is set to open the year in the green, with a series of manufacturing purchasing managers' index readings the first...

IN BRIEF: Hutchmed to get Takeda milestone payment

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical firm - Is to receive a USD10 million milestone payment from partner Takeda Pharmaceutical Co ...

Hutchmed to receive $10m milestone payment from partner Takeda

(Sharecast News) - Hutchmed China announced on Friday that it would receive a $10m milestone payment from its partner Takeda, following a national rei...

LONDON BRIEFING: Sterling suffers as UK economy in surprise shrink

(Alliance News) - London's FTSE 100 is called to open higher on Friday, shaking off poor UK data, a sharp decline in Asian equities, and weaker trade ...

Hutchmed lung cancer therapy gets breakthrough designation in China

(Sharecast News) - Hutchmed China announced on Thursday that the Center for Drug Evaluation of China's National Medical Products Administration (NMPA)...

Hutchmed China injection approval could be a "paradigm shift"

(Alliance News) - Hutchmed China Ltd on Tuesday reported it was granted conditional approval in China for an injection to treat endometrial cancer.

Hutchmed endometrial cancer treatment gets conditional approval in China

(Sharecast News) - Hutchmed China and its partner Innovent Biologics announced conditional approval from China's National Medical Products Administrat...

Hutchmed partner launches Fruzaqla in Japan

(Sharecast News) - Hutchmed China announced the launch of 'Fruzaqla', or fruquintinib, in Japan on Friday by its partner, Takeda, following approval f...